The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000608369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
30/04/2026
Date registered
Help: Date registered
15/05/2026
Date last updated
Help: Date last updated
31/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The Women’s Initiative for Sexual health, Education and Raising awareness of anal cancer (WISER)
Scientific title
The Women’s Initiative for Sexual health, Education and Raising awareness of anal cancer (WISER): an educational intervention to support sexual health in women with anal cancer
Additional trial identifiers [1] 317152 0
Nil
Universal Trial Number (UTN)
Trial acronym
WISER
Related trial records

Health condition
Health condition(s) studied:
Anal Cancer 341735 0
Condition category
Condition code
Cancer 337807 337807 0 0
Bowel - Anal

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
What is the intervention?
The WISER intervention includes a 60-page A5 information resource tailored to address the sexual health, sexual function and intimacy (SFI) information needs of women with anal cancer. The resource includes practical information about vaginal dilators, lubricants, and moisturisers, and shares real-life accounts of women’s experiences of anal cancer treatment.

Who delivers it and their relevant expertise?
The intervention will be delivered by healthcare professionals (HCP), which is anticipated to be primarily radiation oncology nurses. Each site will receive implementation training prior to recruitment. Recognising variability across care settings and professional roles, the WISER implementation training has been developed to support integration of the information booklet into existing clinical workflows, promote confidence among clinicians when introducing and revisiting the booklet, encourage consistent messaging while allowing flexibility in delivery, and reinforce safe practice, scope of practice boundaries, and referral pathways. HCPs who will be involved in the delivery of the WISER intervention will be asked to attend an in-person workshop lasting for a duration of up to 30 mins. Implementation training will be delivered by appropriately trained and qualified members of the Project Management Team prior to recruitment commencing (reflecting staggered recruitment across sites). All participating sites will have access to the implementation materials via an online education platform (Canvas) hosted by the University of Sydney. This platform will allow clinicians to revisit content and access materials as needed throughout the study period, which may be helpful when onboarding new site staff.

How it is delivered?
Face to face delivery, individually in the clinical setting.

How often and for how long?
The booklet will be provided on one occasion prior to patient participants starting radiotherapy treatment, and revisited at least once prior to the end of 6-8 weeks of treatment.
The booklet will initially be provided in a routine appointment lasting up to 45 mins (but may vary depending on treatment location and schedule). It is expected that when the booklet is revisited, it will be at the time of a usual treatment or review appointment lasting approximately 30 mins.

Where it is delivered?
Clinically in the day therapy or radiation oncology unit (usual care).

Adherence
As this is a feasibility study, engagement with the booklet will be monitored by site staff (HCPs), and qualitative information will be collected from patient participants at follow up to determine how often they referred to the booklet during and after their treatment.
Intervention code [1] 333920 0
Treatment: Other
Intervention code [2] 333996 0
Behaviour
Intervention code [3] 333997 0
Rehabilitation
Description of the comparator or control
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345258 0
Patient feasibility (composite outcome to assess overall acceptability and usability of WISER from the patient’s perspective)
Timepoint [1] 345258 0
6-months post treatment commencement.
Primary outcome [2] 345348 0
HCP Feasibility (composite questionnaire to assess overall acceptability and usability of the WISER intervention from the HCP perspective)
Timepoint [2] 345348 0
Immediately post-intervention delivery throughout the course of the study (0-18 months). Where HCPs deliver the intervention more than once, they will be required to complete the questionnaire each time.
Secondary outcome [1] 461125 0
Preliminary efficacy on patient information needs
Timepoint [1] 461125 0
Baseline (pre-treatment) and 3 months post treatment completion.
Secondary outcome [2] 461126 0
Preliminary efficacy of the WISER on HCP’ awareness and confidence in educating women about the impacts of anal cancer treatment (composite outcome).
Timepoint [2] 461126 0
Pre/post implementation training, and post study completion (18 months).
Secondary outcome [3] 461348 0
Preliminary efficacy on patient sexual health outcomes
Timepoint [3] 461348 0
Baseline (pre-treatment), and 1 month and 6 months post treatment completion.
Secondary outcome [4] 461349 0
Preliminary efficacy on patient health-related quality of life (HRQL) outcomes
Timepoint [4] 461349 0
Baseline (pre-treatment), and 3 months and 12 months post treatment completion.
Secondary outcome [5] 461352 0
Patient experiences with the WISER intervention (composite outcome).
Timepoint [5] 461352 0
12 months post treatment completion.
Secondary outcome [6] 461353 0
HCP experiences with the WISER intervention
Timepoint [6] 461353 0
For participating HCPs, interview invitations will be sent 18-months after their recruitment began (site-dependent).

Eligibility
Key inclusion criteria
Two study groups will be recruited:

Adult women (18 or more years old) newly diagnosed with anal cancer (any stage) and planned to receive definitive chemoradiotherapy treatment at participating sites.

HCPs directly involved in the care of patients diagnosed with anal cancer at participating sites involved in delivering patient information and education, including nurses, radiation oncologists, and other cancer specialists.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Adult women younger than 18, with any cancer other than anal cancer.

HCPs (men and women) will only be recruited through participating sites.

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Qualitative: Interviews will be audio-recorded, transcribed and thematically analysed using Framework methodology through the lens of Proctor et al’s implementation outcome taxonomy. We will focus on the Exploration and Preparation phases of the EPIS framework and deductively analyse identified barriers, facilitators, and experiences with the WISER intervention.
Quantitative: Mean percentage changes in continuous outcomes (acceptability and patient-reported outcome measures; PROMs) from pre- to post-intervention (within-individuals) will be estimated using linear mixed models, with a random intercept to account for clustering of observations within individuals. Models will be adjusted by relevant clinical (number of encounters with the resource) and demographic variables such as age, disease stage, site, and others as appropriate. Baseline demographic and clinical data will be summarised descriptively for all patients registered to the study. Clinical significance of differences on the PROMs will be interpreted using existing guidelines.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC
Recruitment hospital [1] 30110 0
GenesisCare - St Leonards - St Leonards
Recruitment hospital [2] 30111 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [3] 30112 0
Westmead Hospital - Westmead
Recruitment hospital [4] 30113 0
Blacktown Hospital - Blacktown
Recruitment hospital [5] 30114 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment hospital [6] 30115 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [7] 30116 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [8] 30117 0
Icon Cancer Centre Concord - Concord
Recruitment hospital [9] 30118 0
Icon Cancer Centre Hobart - Hobart
Recruitment postcode(s) [1] 46505 0
2065 - St Leonards
Recruitment postcode(s) [2] 46506 0
2145 - Westmead
Recruitment postcode(s) [3] 46507 0
2148 - Blacktown
Recruitment postcode(s) [4] 46508 0
3000 - Melbourne
Recruitment postcode(s) [5] 46509 0
5000 - Adelaide
Recruitment postcode(s) [6] 46510 0
5112 - Elizabeth Vale
Recruitment postcode(s) [7] 46511 0
2138 - Concord
Recruitment postcode(s) [8] 46512 0
7000 - Hobart

Funding & Sponsors
Funding source category [1] 321735 0
Government body
Name [1] 321735 0
National Health and Medical Research Council Targeted Call for Research into Anal Cancer
Country [1] 321735 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 324573 0
None
Name [1] 324573 0
Address [1] 324573 0
Country [1] 324573 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320275 0
St Vincent’s Hospital Human Research Ethics Committee
Ethics committee address [1] 320275 0
Ethics committee country [1] 320275 0
Australia
Date submitted for ethics approval [1] 320275 0
28/04/2026
Approval date [1] 320275 0
02/07/2026
Ethics approval number [1] 320275 0
2026/ETH00893

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149954 0
Prof Claudia Rutherford
Address 149954 0
University of Sydney, City Road, Darlington/Camperdown NSW 2006, Australia.
Country 149954 0
Australia
Phone 149954 0
+61 2 86271526
Fax 149954 0
Email 149954 0
Contact person for public queries
Name 149955 0
Claudia Rutherford
Address 149955 0
University of Sydney, City Road, Darlington/Camperdown NSW 2006, Australia.
Country 149955 0
Australia
Phone 149955 0
+61 2 86271526
Fax 149955 0
Email 149955 0
Contact person for scientific queries
Name 149956 0
Claudia Rutherford
Address 149956 0
University of Sydney, City Road, Darlington/Camperdown NSW 2006, Australia.
Country 149956 0
Australia
Phone 149956 0
+61 2 86271526
Fax 149956 0
Email 149956 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.